RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+12.88%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$1.12B
AUM Growth
+$1.12B
(+22%)
Cap. Flow
+$124M
Cap. Flow
% of AUM
11.06%
Top 10 Holdings %
Top 10 Hldgs %
31%
Holding
95
New
1
Increased
36
Reduced
12
Closed
13
Top Buys
| 1 |
BioMarin Pharmaceuticals
BMRN
|
$42.2M |
| 2 |
Medtronic
MDT
|
$9.35M |
| 3 |
Eli Lilly
LLY
|
$8.88M |
| 4 |
Cigna
CI
|
$6.78M |
| 5 |
Cooper Companies
COO
|
$6.74M |
Top Sells
| 1 |
IMMU
Immunomedics Inc
IMMU
|
$20.3M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$7.48M |
| 3 |
Bristol-Myers Squibb
BMY
|
$5.43M |
| 4 |
AIMT
Aimmune Therapeutics, Inc.
AIMT
|
$4.76M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$4.27M |
Sector Composition
| 1 | Healthcare | 94.2% |
| 2 | Communication Services | 2.08% |
| 3 | Industrials | 0.52% |
| 4 | Technology | 0.02% |
| 5 | Energy | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Bristol-Myers Squibb
BMY
$96.7B
| $17.5M | 1.55% |
290,000
-90,000
| -24% | -$5.43M |
|
27
Boston Scientific
BSX
$159B
| $17.2M | 1.53% |
450,000
+40,000
| +10% | +$1.53M |
|
28
Esperion Therapeutics
ESPR
$490M
| $16.9M | 1.5% |
455,000
+30,000
| +7% | +$1.12M |
|
29
Nektar Therapeutics
NKTR
$543M
| $16.6M | 1.48% |
66,667
+14,000
| +27% | +$3.48M |
|
|
XLRN
30
DELISTED
Acceleron Pharma Inc.
XLRN
| $16.3M | 1.45% |
145,000
-10,000
| -6% | -$1.13M |
|
31
MacroGenics
MGNX
$121M
| $16M | 1.42% |
635,711
-39,289
| -6% | -$990K |
|
|
ARNA
32
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $15.8M | 1.4% |
210,778
| – | – |
|
33
Alnylam Pharmaceuticals
ALNY
$58.6B
| $14.6M | 1.29% |
100,000
+37,905
| +61% | +$5.52M |
|
34
CVS Health
CVS
$93B
| $14M | 1.25% |
240,000
+13,000
| +6% | +$759K |
|
|
SGEN
35
DELISTED
Seagen Inc. Common Stock
SGEN
| $13.7M | 1.22% |
70,000
-5,000
| -7% | -$978K |
|
36
Merck
MRK
$210B
| $13.3M | 1.18% |
167,680
| – | – |
|
37
Thermo Fisher Scientific
TMO
$183B
| $13.2M | 1.18% |
30,000
+11,000
| +58% | +$4.86M |
|
38
Regeneron Pharmaceuticals
REGN
$59.8B
| $12.6M | 1.12% |
22,500
+10,000
| +80% | +$5.6M |
|
39
Baxter International
BAX
$12.1B
| $12.5M | 1.11% |
155,000
+60,000
| +63% | +$4.83M |
|
|
ITCI
40
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $12.2M | 1.08% |
475,000
| – | – |
|
41
Iovance Biotherapeutics
IOVA
$800M
| $11.2M | 1% |
340,000
| – | – |
|
42
Zimmer Biomet
ZBH
$20.8B
| $11.2M | 0.99% |
84,460
+25,750
| +44% | +$3.4M |
|
43
Xencor
XNCR
$594M
| $10.1M | 0.9% |
260,000
| – | – |
|
|
AERI
44
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $10M | 0.89% |
850,000
+260,000
| +44% | +$3.06M |
|
45
Edwards Lifesciences
EW
$47.7B
| $9.58M | 0.85% |
120,000
| – | – |
|
46
LivaNova
LIVN
$3.09B
| $9.49M | 0.84% |
210,000
-10,000
| -5% | -$452K |
|
|
SILK
47
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $9.41M | 0.84% |
140,000
| – | – |
|
48
Biogen
BIIB
$20.8B
| $9.36M | 0.83% |
33,000
+16,000
| +94% | +$4.54M |
|
49
HCA Healthcare
HCA
$95.4B
| $9.35M | 0.83% |
75,000
| – | – |
|
50
Intuitive Surgical
ISRG
$158B
| $8.51M | 0.76% |
36,000
-15,000
| -29% | -$3.55M |
|